Calculate the BODE Index for COPD prognosis. Combines BMI, airflow obstruction (FEV₁), dyspnea (mMRC), and exercise capacity (6MWD) for mortality prediction.
The BODE Index Calculator estimates prognosis in chronic obstructive pulmonary disease (COPD) by combining four key variables: Body mass index (B), airflow Obstruction measured by FEV₁ (O), Dyspnea measured by the mMRC scale (D), and Exercise capacity measured by 6-minute walk distance (E). This multidimensional scoring system was developed by Celli et al. in 2004.
Unlike FEV₁ alone, the BODE Index provides a comprehensive assessment of COPD severity by incorporating nutritional status, functional impairment, and exercise tolerance. Scores range from 0 to 10, with higher scores indicating worse prognosis. The index divides patients into four quartiles with dramatically different 4-year survival rates, from approximately 85% in quartile 1 to 20% in quartile 4.
The BODE Index is widely used for prognostication, lung transplant evaluation, and pulmonary rehabilitation assessment, providing clinicians with a validated tool for discussing disease trajectory and treatment intensity with COPD patients. Check the example with realistic values before reporting.
FEV₁ alone captures only one dimension of COPD severity. The BODE Index integrates systemic effects including cachexia (BMI), functional limitation (dyspnea), and deconditioning (exercise capacity). This produces superior mortality prediction compared to any single variable.
The BODE Index guides clinical decisions about treatment escalation, referral for lung transplantation, advance care planning, and pulmonary rehabilitation enrollment. Serial measurements track disease progression and response to therapy.
BODE Index = B + O + D + E B (BMI): ≤21 → 1 pt; >21 → 0 pts O (FEV₁% pred): ≥65 → 0; 50-64 → 1; 36-49 → 2; ≤35 → 3 D (mMRC): 0-1 → 0; 2 → 1; 3 → 2; 4 → 3 E (6MWD): ≥350m → 0; 250-349 → 1; 150-249 → 2; ≤149 → 3 Total Range: 0-10
Result: BODE 3 — Moderate Risk (Quartile 2)
FEV₁ 50% (1 pt) + 6MWD 300m (1 pt) + mMRC 2 (1 pt) + BMI 24.2 (0 pts) = BODE 3. This places the patient in Quartile 2 with approximately 32% 4-year mortality.
Celli et al. (NEJM 2004) validated the BODE Index in 876 COPD patients, demonstrating superior mortality prediction compared to FEV₁ alone. The index was applied to two independent cohorts from the US and Spain, showing consistent predictive power. Each 1-point increase in BODE was associated with a 34% increase in all-cause mortality and a 62% increase in respiratory mortality.
The BODE Index has applications in lung transplant evaluation (ISHLT guidelines), lung volume reduction surgery assessment, pulmonary rehabilitation outcomes, and clinical trial stratification. Changes in BODE after interventions serve as a composite endpoint that captures multiple dimensions of treatment effect.
Alternatives include the ADO Index (Age, Dyspnea, Obstruction), DOSE index (Dyspnea, Obstruction, Smoking, Exacerbations), and the GOLD combined assessment (symptoms + exacerbations). Each has different data requirements and strengths. BODE remains the best-validated tool for prognosis in stable COPD.
The BODE Index is primarily a prognostic tool for COPD. It predicts all-cause and respiratory mortality, helps guide lung transplant listing decisions, assesses pulmonary rehabilitation outcomes, and facilitates shared decision-making about treatment intensity.
Typically annually or after significant clinical changes such as exacerbations, hospitalizations, or completion of pulmonary rehabilitation. Changes of ≥1 point in the BODE Index are clinically meaningful.
Yes. In COPD, low BMI (<21) reflects cachexia from systemic inflammation, increased work of breathing, and poor nutrition. Unlike cardiovascular disease where low BMI is protective, COPD patients with low BMI have significantly worse survival — an "obesity paradox" reversal.
A BODE score of 5-6 is suggested for referral for lung transplant evaluation, while scores of 7-10 indicate that transplant listing should be strongly considered, according to ISHLT guidelines. Use this as a practical reminder before finalizing the result.
No. The modified BODE (mBODE) and BODEx add exacerbation history. The ADO index (Age, Dyspnea, Obstruction) offers another validated alternative. Each tool has strengths for different clinical questions.
Yes. Pulmonary rehabilitation typically improves 6MWD and dyspnea scores. Smoking cessation, bronchodilators, and nutritional support can also improve components. BODE score improvement correlates with better survival.